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of lipid rafts in the entry of HIV-1 into podocytes.
Conditionally immortalized human podocytes were exposed
to primary strains of HIV-1 with different co-receptor
usage—R5 HIV-192US660 and X4 HIV-192HT599. As shown in
Figure 1a, human podocytes exposed to either R5 or X4 viral
strains were positive for HIV-1-specific strong-stop DNA
(LTR RU5).
To determine the role of lipid rafts, we evaluated the effect
of methyl-b-cyclodextrin (MbCD) on podocyte HIV-1 entry.
MbCD is a derivative of cyclic oligosaccharides and has a
lipophilic property that extracts cholesterol from membranes,
resulting in lipid rafts disruption.7 To test the drug effect of
MbCD on mock-infected podocytes, we used the cholera
toxin B-subunit, a specific marker for the lipid rafts
associated GSL GM1.8 MbCD treatment decreased approxi-
mately 70% podocyte cholesterol expression (Figure 1b).
As shown in Figure 1c, podocyte viral accumulation
significantly decreased after MbCD treatment when compared
with the mock-treated control. As cholesterol-replenished
cells (first exposed to cyclodextrin and then replenis-
hed with exogenous water-soluble cholesterol) showed
comparable levels of viral entry (as observed in untreated
cells), it appeared that the inhibition of HIV-1 entry was not
due to the potential toxicity of MbCD (Figure 1d). Inhibi-
tion of viral entry after cholesterol extraction was indepen-
dent of viral tropism (data not shown). These results support
the notion that cholesterol (maintenance of lipid raft
integrity) is required for entry of both X4 and R5 HIV-1.
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The study by Mikulak and Singhal1 showing the impor-
tance of cholesterol in the HIV infection of a human renal
podocyte model system provides additional support for the
important role of cell membrane ‘lipid rafts’ in HIV
infection. Our studies on the binding of R5 gp120 within
the human nephron showed that binding was restricted
to tubular epithelial cells. gp120–tubular cell binding
could be eliminated by detergent extraction of the sections,
suggesting that binding occurred within the non-DRM (‘non-
raft’) fraction. Although podocytes were not specifically
identified in our study, the lack of gp120 glomerular binding
we found indicates that gp120-mediated HIV–podocyte
binding must be significantly less than to renal tubular
epithelial cells.2 The lipid raft requirement for HIV infection
has been contested,3,4 and it may be that the lipid raft
requirement varies between HIV target cell types. In addition,
our studies indicate that Gb3 is a resistance factor against HIV
infection5 rather than a mediator of infection. Thus, there is a
Figure 1 |Role of lipid rafts in podocyte HIV-entry. (a) Podocytes were exposed to different primary human immunodeficiency virus
(HIV)-1 strains: R5 HIV-192US660 and HIV-192HT599. Cells were pulsed with the virus for 24 h followed by washing with phosphate-buffered
saline (PBS), and then treatment with 0.05% trypsin at 37 1C for 10min (to eliminate non-internalized virus). The cells were washed again
four times with PBS and then plated for culture. After 24 h, cells were trypsinized again, washed, lysed, and analyzed for HIV-specific LTR RU5
by PCR. One representative experiment out of three is shown. Mock infection served as a negative control. (b) Equal numbers of podocytes
were incubated in serum-free media (SFM) containing either buffer or methyl-b-cyclodextrin (MbCD, 10mM) for 30min. At the end of the
incubation period, cells were washed and stained with Alexa Fluor 555–conjugated cholera toxin B-subunit (CTx-B) and DAPI. Subsequently,
cells were studied under Zeiss Axiovert (Carl Zeiss, Oberkochen, Germany) 200M with 40 numerical aperture. The presence of podocyte
lipid raft ganglioside GM1 is indicated by red fluorescence, whereas blue fluorescence represents nuclei (DAPI). (c) Podocytes were
pre-incubated in SFM containing either buffer (Control) or MbCD (10mM) for 30min. Subsequently, cells were washed and pulsed with
HIV-192US660 (pre-treated with 200U/ml of RNase-free DNase) for 2 h in SFM. After HIV-1 pulsing, cells were trypsinized, washed, and analyzed
for HIV-1-specific LTR RU5 by PCR. The percent of inhibition represents the percent of the ratio of the relative LTR RU5 c.p.m. units between
samples treated with MbCD and PBS/Control (means±s.d., n¼ 3). (d) After MbCD, treatment podocytes were reconstituted with water-
soluble cholesterol (400 mg/ml) for 2 h, washed, and subsequently incubated in SFM containing HIV-192US660 for 2 h. After HIV-1 pulsing, cells
were trypsinized, washed and analyzed for HIV-1-specific LTR RU5 by PCR. One representative experiment out of three is shown for the
presence of HIV-1-specific strong-stop DNA. Amplification of the a-tubulin gene was used to control for the amount of DNA. The data
represent the means±s.d. of three independent experiments. Mock served as a negative control. *Po0.0001 compared with control.
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significant difference between gp120–cell membrane Gb3
binding and HIV target cell infection. In addition, the known
receptors/co-receptors for gp120 on T cells can be expressed
within the non-DRM fraction and then recruited to detergent
resistant membranes after gp120–viral target cell binding,6 and
so initial binding within the non-detergent resistant mem-
brane fraction does not exclude a later role for cholesterol in
HIV internalization.
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To the Editor: I have read with great interest the article
published recently in your esteemed journal entitled ‘The
Oxford classification of IgA nephropathy: rationale, clinico-
pathologic correlations, and classification’.1 This is a unique
and huge effort by the members of the International IgA
Nephropathy Working Group in trying to standardize the
reporting of pathological criteria of importance in the
prognostication of this most common form of primary
glomerulopathy worldwide.2 I have a few points to make
regarding the nomenclature of this scheme. I understand that
these are conceptual and related to nomenclature, rather than
substantial and related to contents of the study, and that they
merit some consideration by the worthy authors of this
scheme. The points are as follows:
(1) I believe this effort is not the so-called ‘splitters’
approach to classification of diseases, inasmuch as no
artificial classes are defined and the cases are lumped into
these. The approach adopted in this classification is more
akin to the Revised European-American Classification of
Lymphoid Neoplasms (REAL) by the World Health
Organization3 and is much more sensible. As such, its
nomenclature could preferably be changed to ‘consensus
schema’ or ‘formulation’ to truly reflect the unique
endeavor and the methodology adopted in this effort, or
else it could be changed to ‘working classification’ for the
following reasons.
(2) I also assume this is not an end point classification of IgA
nephropathy (IgAN). There is certainly room for
evolution, as the authors also agree in discussion, as
more realistic validation studies are being carried out on
a wide spectrum of cases in routine clinical practice in
different parts of the world. Moreover, the contribution
of immunofluorescence and electron microscopic studies
has not been evaluated in this schema. It will be worth
exploring this aspect of the study of IgAN to see if they
add any value to mere light microscopic scoring of the
renal biopsies adopted in this classification. The future
will definitely see more molecular genetic studies further
refining the crude prognostic criteria that we have at
hand now and true prognostic classes of IgAN may
emerge. Retention of the word ‘classification’ in the
option of nomenclature of ‘working classification’ will
prevent us from repenting in future for not using it,
should this picture emerge in future. This approach has
been successfully adopted by the Banff working classifi-
cation of renal allograft pathology.4
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We thank Dr Muhammed Mubarak1 for his comments
regarding our new classification of immunoglobulin A
nephropathy.2 We agree that optional words could have
been used and were explored. This is why, in part, there are
additional descriptors in the title to help explain what we
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